Thromboembolic complications related to central venous access catheters in cancer patients

Seminars in Thrombosis and Hemostasis

Volumn 33, Issue 4, 2007, Pages 389-396

  Freytes, César O ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mail Code 7880 ^*  (United States)

Author keywords

Central venous catheterization; Indwelling catheters; Neoplasm; Thrombolytic therapy; Venous thrombosis

Indexed keywords

ALTEPLASE; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; CANCER PATIENT; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; COLOR ULTRASOUND FLOWMETRY; DEEP VEIN THROMBOSIS; FIBRINOLYTIC THERAPY; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PHLEBOGRAPHY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM;

ANTICOAGULANTS; CATHETERIZATION, CENTRAL VENOUS; CATHETERS, INDWELLING; HUMANS; NEOPLASMS; THROMBOEMBOLISM;

EID: 34249949847     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-976174     Document Type: Review

References (76)

1. Hoshal VL Jr, Ause RG, Hoskins PA. Fibrin sleeve formation of indwelling subclavian central venous catheters. Arch Surg 1971;102:253-258
2. Balestreri L, De Cicco M, Matovic M, et al. Central venous catheter-related thrombosis in clinically asymptomatic oncologic patients: a phlebographic study. Eur J Radiol 1995;20: 108-111
3. De Cicco M, Matovic M, Balestreri L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 1997;86:101-113
4. Xiang DZ, Verbeken EK, van Lommel AT, et al. Composition and formation of the sleeve enveloping a central venous catheter. J Vasc Surg 1998;28:260-271
5. Forauer AR, Theoharis CG, Dasika NL. Jugular vein catheter placement: histologic features and development of catheter-related (fibrin) sheaths in a swine model. Radiology 2006;240:427-434
6. Starkhammar H, Bengtsson M, Morales O. Fibrin sleeve formation after long-term brachial catheterization, with implantable port device. A prospective venographic study. Eur J Surg 1992;158:481-484
7. Raad II, Luna M, Khalil SA, et al. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994;271:1014-1016
8. Hurtubise MR, Bottino JC, Lawson M, et al. Restoring patency of occluded central venous catheters. Arch Surg 1980;115:212-213
9. Hooke C. Recombinant tissue plasminogen activator for central venous access device occlusion. J Pediatr Oncol Nurs 2000;17:174-178
10. Stephens LC, Haire WD, Kotulak GD. Are clinical signs accurate indicators of the cause of central venous catheter occlusion? JPEN J Parenter Enteral Nutr 1995;19:75-79
11. Schifferdecker B, Shaw JA, Piemonte TC, Eisenhauer AC. Nonmalignant superior vena cava syndrome. Pathophysiology and management. Catheter Cardiovasc Interv 2005;65:416-442
12. Monreal M, Lafoz E, Ruiz J, et al. Upper extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991;99:280-283
13. Prandoni P, Bernardi E, Marchiori A, et al. The long-term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004;329:484-485
14. Bernardi E, Pesavento R, Prandoni P. Upper extremity deep vein thrombosis. Semin Thromb Hemost 2006;32:729-736
15. Agnelli G, Verso M. Therapy insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 2006;3:214-222
16. Bozzetti F, Scarpa D, Terno GJ, et al. Subclavian venous thrombosis due to indwelling catheters: a prospective study on 52 patients. JPEN J Parenter Enteral Nutr 1983;7:560-562
17. Lokich JJ, Becker B. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy. Cancer 1983;52:1586-1589
18. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112: 423-428
19. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251-253
20. Horne MK III, May DJ, Alexander HR, et al. Venographic surveillance of tunneled venous access devices in adult oncology patients. Ann Surg Oncol 1995;2:174-178
21. Barzaghi A, Dell'Orto M, Rovelli A, et al. Central venous catheter clots: incidence, clinical significance and catheter care in patients with hematologic malignancies. Pediatr Hematol Oncol 1995;12:243-250
22. Glaser DW, Medeiros D, Rollins N, Buchanan GR. Catheter-related thrombosis in children with cancer. J Pediatr 2001;138:255-259
23. Haire WD, Lieberman RP, Edney J, et al. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990;66:900-908
24. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004;9:207-216
25. Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-4069
26. Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404-1408
27. Biffi R, De Braud F, Orsi F, et al. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. Cancer 2001;92:1204-1212
28. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo controlled, randomized study in cancer patients. J Clin Oncol 2005;23: 4057-4062
29. Karthaus M, Kretzchmar A, Kroning A, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-296
30. Levine M, Kakkar AK. Catheter-associated thrombosis: thromboprophylaxis or not? J Clin Oncol 2005;23:4006-4008
31. Prandoni P, Polistena P, Bernardi E, et al. Upper extremity deep vein thrombosis. Risk factors, diagnosis and complications. Arch Intern Med 1997;157:57-62
32. Koksoy C, Kuzu A, Kutlay J, et al. The diagnostic value of colour Doppler ultrasound in central venous catheter related thrombosis. Clin Radiol 1995;50:687-689
33. Gaitini D, Beck-Razi N, Haim N, Brenner B. Prevalence of upper extremity deep venous thrombosis diagnosed by color duplex sonography in cancer patients with central venous catheters. J Ultrasound Med 2006;25:1297-1303
34. Male C, Chait P, Ginsberg JS, et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body of children: results of the PARKAA study. Thromb Haemost 2002;87:593-598
35. Kroencke TJ, Taupitz M, Arnold R, Fritsche L, Hamm B. Three-dimensional gadolinium-enhanced magnetic resonance venography in suspected thrombo-occlusive disease of the central chest veins. Chest 2001;120:1570-1576
36. Thornton MJ, Ryan R, Varghese JC, et al. A three-dimensional gadolinium-enhanced MR venography technique for imaging central veins. AJR Am J Roentgenol 1999; 173:999-1003
37. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675
38. Adess M, Eisner R, Nand S, et al. Thromboembolism in cancer patients: pathogenesis and treatment. Clin Appl Thromb Hemost 2006;12:254-266
39. Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002;118:267-270
40. Riordan M, Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol 1998;58:150-152
41. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004;15:590-593
42. Abdelkefi A, Ben Romdhane N, Kriaa A, et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005;36: 885-889
43. Tesselaar ME, Ouwerkerk J, Nooy MA, et al. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 2004;40:2253-2259
44. Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004;15:590-593
45. van Rooden CJ, Rosendaal FR, Meinders AE, et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004;89:201-206
46. Wermes C, von Depka Prondzinski M, Lichtinghagen R, et al. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters. Eur J Pediatr 1999;158(suppl 3):S43-146
47. Eastman ME, Khorsand M, Maki DG, et al. Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2. Cancer 2001;91:806-814
48. Stephens LC, Haire WD, Schmit-Pokorny K, Kessinger A, Kotulac G. Granulocyte macrophage colony stimulating factor: high incidence of apheresis catheter thrombosis during peripheral stem cell collection. Bone Marrow Transplant 1993;11:51-54
49. Borow M, Crowley JG. Evaluation of central venous catheter thrombogenicity. Acta Anaesthesiol Scand Suppl 1985;81: 59-64
50. Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995;13:233-238
51. Brown-Smith JK, Stoner MH, Barley ZA. Tunneled catheter thrombosis: factors related to incidence. Oncol Nurs Forum 1990;17:543-549
52. Craft PS, May J, Dorigo A, Hoy C, Plant A. Hickman catheters: left sided insertion, male gender and obesity are associated with an increased risk of complications. Aust N Z J Med 1996;26:33-39
53. Male C, Chait P, Andrew M, et al. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 2003; 101:4273-4278
54. McBride KD, Fisher R, Warnock N, et al. A comparative analysis of radiological and surgical placement of central venous catheters. Cardiovasc Intervent Radiol 1997;20: 17-22
55. van Rooden CJ, Schippers EF, Barge RM, et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:2655-2660
56. Journeycake JM, Buchanan GR. Catheter-related deep venous thrombosis and other complications in children with cancer. J Clin Oncol 2006;24:4575-4580
57. Trerotola SO, Kuhn-Fulton J, Johnson MS, et al. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology 2000;217:89-93
58. MacDonald S, Watt AJ, McNally D, Edwards RD, Moss JG. Comparison of technical success and outcome of tunneled catheters inserted via the jugular and subclavian approaches. J Vasc Interv Radiol 2000;11:225-231
59. Nightingale CE, Norman A, Cunningham D, et al. A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy. Eur J Cancer 1997;33:398-403
60. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112: 423-428
61. Boraks P, Seale J, Price J, et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with hematologic malignancies. Br J Haematol 1998; 101:483-486
62. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J 2002;32:84-88
63. Mismetti P, Mille D, Laporte S, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica 2003;88:67-73
64. Agnelli G, Verso M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? No. J Thromb Haemost 2006;4:14-15
65. Levine M. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Still an open question. J Thromb Haemost 2006;4:16-18
66. Huisman MV. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups. J Thromb Haemost 2006;4:10-13
67. Timoney JP, Malkin MG, Leone DM, et al. Safe and cost effective use of alteplase for the clearance of occluded central venous devices. J Clin Oncol 2002;20:1918-1922
68. Haire WD, Deitcher SR, Mullane KM, et al. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost 2004;92:575-582
69. Moll S, Kenyon P, Bertoli L, et al. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded venous devices. J Clin Oncol 2006;24:3056-3060
70. Linenberger ML. Catheter-related thrombosis: risks, diagnosis and management. J Natl Compr Canc Netw 2006; 4:889-901
71. Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999;82:1008-1010
72. Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD. The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis 2000;10:271-275
73. Sabeti S, Schillinger M, Miekusch W, Haumer M, Ahmadi R, Minar E. Treatment of subclavian-axillary thrombosis: long-term outcome of anticoagulation versus thrombosis. Thromb Res 2002;108:279-285
74. Spence LD, Gironta MG, Malde HM, et al. Acute upper extremity deep vein thrombosis: safety and effectiveness of superior venal cava filters. Radiology 1999;210:53-58
75. Ascher E, Hingorani A, Mazzariol F, et al. Clinical experience with superior vena caval Greenfield filters. J Endovasc Surg 1999;6:365-369
76. Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006;4:838-869